Neurizon Therapeutics (ASX:NUZ)
ASX announcement history & article coverage
Transparent by design.
Announcments by Neurizon Therapeutics (ASX:NUZ) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Application for quotation of securities - NUZ
Appendix 4G and Corporate Governance Statement
Appendix 4E and 2026 Annual Report
Neurizon Therapeutics reports FY2026 results, completes HEALEY ALS trial enrolment, and advances NUZ-001 clinical development
Notification regarding unquoted securities - NUZ
Elanco representative appointed as Neurizon Board Observer
Neurizon Completes Initial Drawdown under R&D Facility
Appendix 4C & Quarterly Update
Neurizon Enters Strategic R&D Financing Facility
Neurizon secures $17.5 million R&D financing facility with Dare Capital
Melbourne investor briefing presentation
HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27
Neurizon completes fastest enrolment in HEALEY ALS trial, accelerates topline results to Q2 2027
Application for quotation of securities - NUZ
Notification of cessation of securities - NUZ
Neurizon Invites Investors to Melbourne Briefing
Change of Director's Interest Notice
Proposed issue of securities - NUZ
Notification of cessation of securities - NUZ
New NUZ-001 Mechanistic Data Presented at BIO 2026
Application for quotation of securities - NUZ
Neurizon executes long-term supply agreement with Elanco
Neurizon secures five-year supply agreement with Elanco to advance NUZ-001 commercialisation
HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule
Neurizon surpasses 50% dosing milestone in HEALEY ALS Platform Trial ahead of schedule
